PR Newswire·Nov 9, 2026, 8:25 AM ET

IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

IceCure Medical received a new patent from the China National Intellectual Property Administration (CNIPA) for a connector used in its cryogenic technology platform.
The patent grant brings IceCure's total intellectual property portfolio to 42 patents across the U.S., Europe, Great Britain, China, & Japan.
This patent follows the September 2026 approval by China's National Medical Products Administration for IceCure to market its ProSense system & associated cryoprobes in China.
The company's proprietary portfolio covers its technological platform & innovations intended for current & future products.
IceCure develops liquid-nitrogen-based cryoablation systems primarily for treating breast, kidney, bone, & lung cancers.
ProSense is the first-and-only FDA-cleared device for treating low-risk breast tumors ≤1.5 cm in patients aged 70+ undergoing adjuvant endocrine therapy.